Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T05:18:11.330Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacoeconomic Studies: Pitfalls and Problems

Published online by Cambridge University Press:  10 March 2009

Diana De Graeve  and
Walter Nonneman
Diana De Graeve
Affiliation:
University of Antwerp
Walter Nonneman
Affiliation:
University of Antwerp
Get access Rights & Permissions [Opens in a new window]

Abstract

The literature on economic evaluation of Pharmaceuticals is growing rapidly. Although there have been substantial methodologic advances, there remain serious problems and pitfalls. This presentation focuses on three aspects, i.e., use (and abuse) of evaluation studies, methodologic problems, and the quality of published studies.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 12 , Issue 1 , Winter 1996 , pp. 22 - 30
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Adams, M., McCall, N., & Gray, D.Economic analysis in randomized control trials. Medical Care, 1992, 30, 231–43.CrossRefGoogle ScholarPubMed
2.Broome, J.QALYs. Journal of Public Economics, 1992, 50, 149–67.CrossRefGoogle Scholar
3.Drummond, M.Economic evaluation of Pharmaceuticals: Science or marketing? PharmacoEconomics, 1992, 1, 8–13.CrossRefGoogle ScholarPubMed
4.Drummond, M., Rutter, F., Brenna, A. et al. Economic evaluation of Pharmaceuticals: A European perspective. PharmacoEconomics, 1993, 4, 173–86.CrossRefGoogle ScholarPubMed
5.Drummond, M., & Davies, L.Economic analysis alongside clinical trials: Revisiting the methodological issues. International Journal of Technology Assessment in Health Care, 1991, 7, 561–73.CrossRefGoogle ScholarPubMed
6.Drummond, M. G., Stoddart, G., & Torrance, G. W.Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications, 1987.Google Scholar
7.Gramlich, E. M.A guide to benefit-cost analysis. Englewood Cliffs, NJ: Prentice Hall, 1990.Google Scholar
8.Guyatt, G., Drummond, M., Feeny, D. et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine, 1986, 22, 393–408.CrossRefGoogle ScholarPubMed
9. Henry, D. Economic analysis as an aid to subsidization: The development of Australian guidelines for Pharmaceuticals. PharmacoEconomics, 1992, 54–67.CrossRefGoogle Scholar
10.Hillman, A., Eisenberg, J., Pauly, M. et al. Avoiding bias in the conduct of cost effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine, 1991, 324, 1362–65.CrossRefGoogle ScholarPubMed
11.Hutton, J.Economic evaluation of health care: A half-way technology. Health Economics, 1994, 3, 1–4.CrossRefGoogle ScholarPubMed
12.Jonsson, B.Cost-benefit analysis of hepatitis B vaccination. Postgraduate Medical Journal, 1987, 63(suppl. 2), 27–32.Google ScholarPubMed
13.Katz, D. A., & Welch, G.Discounting in cost-effectiveness analysis of health care programs. PharmacoEconomics, 1993, 3, 276–85.CrossRefGoogle Scholar
14.Mooney, G., & Olson, J. A. QALYs: Where next? In Mcguire, A.Fenn, P., & Meyhew, K. (eds.) Providing health care. Oxford: Oxford University Press, 1991, 120–40.Google Scholar
15.Nord, E.Toward quality assurance in QALY calculations. International Journal of Technology Assessment in Health Care, 1993, 9, 37–45.CrossRefGoogle ScholarPubMed
16.Nord, E., Richardson, J., & Macarounas-Kirchman, K.Social evaluation of health care versus personal evaluation of health states: Evidence on the validity of four health-state scaling instruments using Norwegian and Australian data. International Journal of Technology Assessment in Health Care, 1993, 9, 463–78.CrossRefGoogle Scholar
17. OECD. Managing with market-type mechanisms. Paris: Public Management Studies, 1993.Google Scholar
18.Olson, J. A.Persons versus years: Two ways of eliciting implicit weights. Health Economics,1994, 3, 39–46.CrossRefGoogle Scholar
19.Petrou, S., Malek, M., & Davey, P. G.The reliability of cost-utility estimates in cost-per-QALY league tables. PharmacoEconomics, 1993, 3, 345–53.CrossRefGoogle ScholarPubMed
20.Russell, L. B.Is prevention better than cure? Washington, DC: The Brookings Institution, 1986.Google Scholar
21.Scherer, F. M.Pricing, profits and technological progress in the pharmaceutical industry. Journal of Economic Perspectives, 1993, 7, 97–115.CrossRefGoogle Scholar
22.Sheldon, T. A.Discounting in health care decision-making: Time for a change? Journal of Public Health Medicine, 1992, 14, 250-56.Google ScholarPubMed
23.Smith, R. D., & Dobson, M.Measuring utility values for QALYs: Two methodological issues. Health Economics, 1993, 2, 349–55.CrossRefGoogle ScholarPubMed
24.Udvarhelyi, S., Colditz, G., Rai, A. et al. Cost-effectiveness and cost-benefit analysis in the medical literature: Are the methods being used correctly? Annals of Internal Medicine, 1992, 116, 238–44.CrossRefGoogle ScholarPubMed
25.Weinstein, M.Principles of cost-effective resource allocation in health care organizations. International Journal of Technology Assessment in Health Care, 1990, 6, 93–103.CrossRefGoogle ScholarPubMed
26.Weinstein, M., & Fineberg, H. V.Clinical decision analysis. New York: W. B. Saunders, 1980.Google Scholar
27.Weisbrod, B. A.The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature, 1991, 24, 523–52.Google Scholar